121 completed, 15 unknown, 8 recruiting, 8 withdrawn. 167 Phase 1, 37 Phase 2.
Follow Parkinson's Disease: new trials by email Literature Review of Parkinson's Disease trials Research Report on Parkinson's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease RO7568282, Placebo - Parkinson's Disease | Phase 1 / Phase 2 | Not yet recruiting | Hoffmann-La Roche | 474 | 2026-09-30 | 2026-10-20 |
| Terazosin And Metabolic Engagement in Parkinson's Disease Terazosin Hydrochloride, Placebo - Parkinson's Disease | Phase 1 / Phase 2 | Withdrawn | Nandakumar Narayanan | 2026-09-01 | 2026-10-07 | |
| Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease UX-DA003 - Parkinson's Disease | Phase 1 / Phase 2 | Not yet recruiting | Shanghai UniXell Biotechnology Co., Ltd | 12 | 2026-08-03 | 2026-07-29 |
| An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination. TRB-001 - Parkinson's Disease | Phase 1 | Recruiting | Tridem Bioscience FlexCo | 6 | 2026-07-28 | 2026-09-10 |
| Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients IPS101A - Parkinson Disease, Parkinson's Disease | Phase 1 | Recruiting | Innopeutics Corporation | 6 | 2026-05-30 | 2026-04-21 |
| The Safety,Tolerability, Efficacy of XS411 Cell Injection for the Treatment of Primary Parkinson's Disease human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection - Parkinson's Disease | Phase 1 / Phase 2 | Active not recruiting | XellSmart Therapeutics (Shanghai) Co., Ltd. | 39 | 2025-08-05 | 2026-09-30 |
| A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery Reparative Autologous peripheral nerve tissue - Parkinson's Disease | Phase 1 | Recruiting | Craig van Horne, MD, PhD | 24 | 2025-07-21 | 2026-08-31 |
| A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease DSP-1083 implantation, Sham surgery treatment - Parkinson's Disease | Phase 1 / Phase 2 | Recruiting | Sumitomo Pharma America, Inc. | 25 | 2024-12-18 | 2026-10-21 |
| A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease VGN-R09b - Parkinson's Disease | Phase 1 / Phase 2 | Active not recruiting | Shanghai Vitalgen BioPharma Co., Ltd. | 39 | 2024-09-02 | 2026-03-31 |
| A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease LY3962681, Placebo (aCSF) - Parkinson's Disease | Phase 1 | Recruiting | Prevail Therapeutics | 124 | 2024-08-27 | 2026-10-16 |
| A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JX2105 in Healthy Chinese Subjects JX2105, Placebo - Parkinson's Disease | Phase 1 | Unknown | Zhejiang Jingxin Pharmaceutical Co., Ltd. | 52 | 2024-07-01 | 2024-08-05 |
| Repurposing Lithium for Parkinson's Disease Lithium aspartate - Parkinson's Disease | Phase 1 | Completed | State University of New York at Buffalo | 15 | 2023-10-12 | 2026-05-13 |
| Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease AAV-GAD - Parkinson's Disease | Phase 1 / Phase 2 | Active not recruiting | MeiraGTx, LLC | 13 | 2023-05-19 | 2026-09-01 |
| Study to Evaluate the Safety and Efficacy of ESC-derived Dopamine Progenitor Cell Therapy in PD Patients Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) Low Dose, Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) High Dose - Parkinson's Disease | Phase 1 / Phase 2 | Completed | S.Biomedics Co., Ltd. | 12 | 2023-05-09 | 2026-04-13 |
| Relative Bioavailability and Food Effect Study of CVN424 CVN424 - Parkinson's Disease | Phase 1 | Completed | Cerevance Beta, Inc. | 32 | 2022-10-09 | 2024-09-19 |
| A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants AAV-GAD Low Dose, AAV-GAD High Dose, Sham Surgery - Parkinson's Disease | Phase 1 / Phase 2 | Completed | MeiraGTx, LLC | 14 | 2022-10-05 | 2025-09-05 |
| Home-based Transcranial Static Magnetic Field Stimulation (tSMS) of the Supplementary Motor Area in Parkinson's Disease Transcranial static magnetic field stimulation (tSMS) of the supplementary motor area - Parkinson's Disease | Phase 1 | Unknown | Fundación de investigación HM | 20 | 2022-10-01 | 2025-02-21 |
| A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension HNC364 - Parkinson's Disease | Phase 1 | Completed | Guangzhou Henovcom Bioscience Co. Ltd. | 34 | 2022-08-22 | 2024-09-27 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers MT101-5 - Parkinson's Disease | Phase 1 | Completed | Mthera Pharma Co., Ltd. | 48 | 2022-07-11 | 2023-05-06 |
| Feasibility and Safety of autoloGous UncondItioneD pEripheral Nerve Tissue Delivery to the Substantia Nigra (GUIDE) Peripheral Nerve Tissue Implantation - Parkinson's Disease | Phase 1 | Active not recruiting | Craig van Horne, MD, PhD | 10 | 2022-07-07 | 2026-08-31 |
Showing 20 of 167. Sign in to see all of them.
Parkinson Disease (167) · Movement Disorders (5) · Dyskinesias (4) · Cognitive Dysfunction (3) · Cough (3) · Alzheimer Disease (2) · Constipation (2) · Depression (2) · Hypotension, Orthostatic (2) · Lewy Body Disease (2) · Parkinsonian Disorders (2) · Speech (2) · Autoimmune Lymphoproliferative Syndrome, Type IA (1) · Basal Ganglia Diseases (1) · Brain Diseases (1)
Synucleinopathies (167) · Basal Ganglia Diseases (166) · Brain Diseases (166) · Central Nervous System Diseases (166) · Nervous System Diseases (166) · Neurodegenerative Diseases (166) · Parkinsonian Disorders (165) · Movement Disorders (162) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (13) · Neurologic Manifestations (9) · Mental Disorders (5) · Neurocognitive Disorders (5) · Behavior (4) · Cognition Disorders (3)
carbidopa, levodopa drug combination (9) · Carbidopa (7) · Levodopa (7) · nebicapone (7) · rotigotine (6) · entacapone (4) · opicapone (3) · Rifampin (2) · Sodium Chloride (2) · Stalevo (2) · rasagiline (2) · (11C)-MC1 (1) · 11C-PS13 (1) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · 4-methylbenzyl 3-fluoro-4-((pyrimidin-2-ylamino)methyl)piperidine-1-carboxylate (1)
Bial - Portela C S.A. (10) · NeuroDerm Ltd. (7) · Kyowa Kirin Co., Ltd. (5) · Affiris AG (4) · University of Florida (4) · AstraZeneca (3) · Biogen (3) · Craig van Horne, MD, PhD (3) · Luye Pharma Group Ltd. (3) · National Institute of Neurological Disorders and Stroke (NINDS) (3) · Neurocrine Biosciences (3) · Newron Sweden AB (3) · Orion Corporation, Orion Pharma (3) · UCB Pharma (3) · VA Office of Research and Development (3)
United States (77) · United Kingdom (18) · China (11) · Germany (9) · Japan (7) · Israel (6) · Netherlands (6) · Austria (5) · France (5) · Portugal (5) · Canada (4) · South Korea (4) · Sweden (4) · Finland (3) · Australia (2)
Craig van Horne, MD, PhD (2) · Dieter Volc, Prim. Dr. (2) · Mika Scheinin, MD (2) · Roongroj Bhidayasiri, MD, FRCP (2) · Stephane Palfi, Professor (2) · Steve Hersch, MD (2) · Abrahan N Lieberman, MD (1) · Achim Schneeberger, Dr. (1) · Albert Lo, MD PhD (1)
PMID 30741694, PMID 23860343, PMID 24412048, PMID 31127735, PMID 40680102, PMID 10816186, PMID 11408093, PMID 12112073, PMID 1362956, PMID 1454205, PMID 16324089, PMID 17586305, PMID 18387850, PMID 18650802, PMID 18695057, PMID 19029430, PMID 19077238, PMID 19230029, PMID 19491335, PMID 20065126, PMID 20213818, PMID 20228251, PMID 20925125, PMID 20946640, PMID 21474638, PMID 21484351, PMID 21795440, PMID 21834011, PMID 22401642, PMID 23240940, PMID 24006953, PMID 25689258, PMID 25791613, PMID 26171276, PMID 27591395, PMID 27886407, PMID 29059133, PMID 29461870, PMID 29910127, PMID 29913017, PMID 30361858, PMID 30363894, PMID 30802998, PMID 31133957, PMID 31356217, PMID 32482490, PMID 33029934, PMID 33921079, PMID 34000076, PMID 34316590
2014 (4), 2009 (1), 2015 (1), 2016 (1), 2018 (1), 2025 (1), I01RX003397 (1), IK2RX002938 (1), R01AG081356 (1), R01NS034239 (1), R01NS052318 (1), R21DC014567 (1), U54NS065768 (1), UL1TR001412 (1)